Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy

Authors

  • Davide Franceschini IRCCS Humanitas Research Hospital, Milan, Italy
  • Vanessa Polenghi MOX lab, Department of Mathematics, Politecnico di Milano, Milano, Italia
  • Ciro Franzese IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy
  • Tiziana Comito IRCCS Humanitas Research Hospital, Milan, Italy
  • Pierina Navarria IRCCS Humanitas Research Hospital, Milan, Italy
  • Giuseppe R. D’Agostino IRCCS Humanitas Research Hospital, Milan, Italy
  • Francesca Ieva MOX lab, Department of Mathematics, Politecnico di Milano, Milano, Italia; CADS – Center for Analysis, Decisions and Society, Human Technopole, Milan, Italy
  • Marta Scorsetti IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy

DOI:

https://doi.org/10.1080/0284186X.2022.2042475

Keywords:

Oligometastases, stereotactic body radiotherapy, prognostic score, prognostic factors

Abstract

Background

to find clinical features that can predict prognosis in patients with oligometastatic disease treated with stereotactic body radiotherapy (SBRT)

Material and methods

Patients with less than 5 metastases in less than 3 different body sites were included in the analysis. Various clinical and treatment parameters were analyzed to create a Cox proportional hazard model for Overall Survival (OS). Subsequently, significant variables were used to create a score

Results

997 patients were analyzed. Median OS was 2.61 years, 1 and 3 years OS was respectively 85% and 43%. Location of the primary tumor, performance status, site of irradiated metastases, presence of extratarget non irradiated lesions and RT dose were significant prognostic factors for OS. These parameters were used to create a score and to distinguish three different classes, with median OS of 5.67 years in low risk, 2.47 years in intermediate risk and 1.82 years in high risk group.

Conclusion

moving from easily accessible clinical parameters, a score was created to help the physician’s decision about the better treatment or combination of treatments for the individual patient.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2022-05-04

How to Cite

Franceschini, D., Polenghi, V., Franzese, C., Comito, T., Navarria, P., D’Agostino, G. R., … Scorsetti, M. (2022). Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. Acta Oncologica, 61(5), 553–559. https://doi.org/10.1080/0284186X.2022.2042475